PURPOSE: α2C-Adrenoceptors share inhibitory presynaptic functions with the more abundant α2A-adrenoceptor subtype, but they also have widespread postsynaptic modulatory functions in the brain. Research on the noradrenergic system of the human brain has been hampered by the lack of suitable PET tracers targeted to the α2-adrenoceptor subtypes. METHODS: PET imaging with the specific α2C-adrenoceptor antagonist tracer [(11)C]ORM-13070 was performed twice in six healthy male subjects to investigate the test-retest reliability of tracer binding. RESULTS: The bound/free ratio of tracer uptake relative to nonspecific uptake into the cerebellum during the time interval of 5 - 30 min was most prominent in the dorsal striatum: 0.77 in the putamen and 0.58 in the caudate nucleus. Absolute test-retest variability in bound/free ratios of tracer ranged from 4.3 % in the putamen to 29 % in the hippocampus. Variability was also <10 % in the caudate nucleus and thalamus. Intraclass correlation coefficients (ICC) ranged from 0.50 in the hippocampus to 0.89 in the thalamus (ICC >0.70 was also reached in the caudate nucleus, putamen, lateral frontal cortex and parietal cortex). The pattern of [(11)C]ORM-13070 binding, as determined by PET, was in good agreement with receptor density results previously derived from post-mortem autoradiography. PET data analysis results obtained with a compartmental model fit, the simplified reference tissue model and a graphical reference tissue analysis method were convergent with the tissue ratio method. CONCLUSION: The results of this study support the use of [(11)C]ORM-13070 PET in the quantitative assessment of α2C-adrenoceptors in the human brain in vivo. Reliable assessment of specific tracer binding in the dorsal striatum is possible with the help of reference tissue ratios.
PURPOSE: α2C-Adrenoceptors share inhibitory presynaptic functions with the more abundant α2A-adrenoceptor subtype, but they also have widespread postsynaptic modulatory functions in the brain. Research on the noradrenergic system of the human brain has been hampered by the lack of suitable PET tracers targeted to the α2-adrenoceptor subtypes. METHODS: PET imaging with the specific α2C-adrenoceptor antagonist tracer [(11)C]ORM-13070 was performed twice in six healthy male subjects to investigate the test-retest reliability of tracer binding. RESULTS: The bound/free ratio of tracer uptake relative to nonspecific uptake into the cerebellum during the time interval of 5 - 30 min was most prominent in the dorsal striatum: 0.77 in the putamen and 0.58 in the caudate nucleus. Absolute test-retest variability in bound/free ratios of tracer ranged from 4.3 % in the putamen to 29 % in the hippocampus. Variability was also <10 % in the caudate nucleus and thalamus. Intraclass correlation coefficients (ICC) ranged from 0.50 in the hippocampus to 0.89 in the thalamus (ICC >0.70 was also reached in the caudate nucleus, putamen, lateral frontal cortex and parietal cortex). The pattern of [(11)C]ORM-13070 binding, as determined by PET, was in good agreement with receptor density results previously derived from post-mortem autoradiography. PET data analysis results obtained with a compartmental model fit, the simplified reference tissue model and a graphical reference tissue analysis method were convergent with the tissue ratio method. CONCLUSION: The results of this study support the use of [(11)C]ORM-13070 PET in the quantitative assessment of α2C-adrenoceptors in the human brain in vivo. Reliable assessment of specific tracer binding in the dorsal striatum is possible with the help of reference tissue ratios.
Authors: Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson Journal: J Cereb Blood Flow Metab Date: 2007-05-09 Impact factor: 6.200
Authors: A Breier; T P Su; R Saunders; R E Carson; B S Kolachana; A de Bartolomeis; D R Weinberger; N Weisenfeld; A K Malhotra; W C Eckelman; D Pickar Journal: Proc Natl Acad Sci U S A Date: 1997-03-18 Impact factor: 11.205
Authors: Veronica Fagerholm; Johanna Rokka; Leena Nyman; Jukka Sallinen; Jari Tiihonen; Erkki Tupala; Merja Haaparanta; Jarmo Hietala Journal: Synapse Date: 2008-07 Impact factor: 2.562
Authors: A A Lammertsma; C J Bench; S P Hume; S Osman; K Gunn; D J Brooks; R S Frackowiak Journal: J Cereb Blood Flow Metab Date: 1996-01 Impact factor: 6.200
Authors: Anna Krzyczmonik; Thomas Keller; Francisco R López-Picón; Sarita Forsback; Anna K Kirjavainen; Jatta S Takkinen; Aleksandra Wasilewska; Mika Scheinin; Merja Haaparanta-Solin; Franciszek Sączewski; Olof Solin Journal: Mol Imaging Biol Date: 2019-10 Impact factor: 3.488
Authors: Jussi Lehto; Jarkko Johansson; Lauri Vuorilehto; Pauliina Luoto; Eveliina Arponen; Harry Scheinin; Juha Rouru; Mika Scheinin Journal: Psychopharmacology (Berl) Date: 2015-04-29 Impact factor: 4.530
Authors: Sjoerd J Finnema; Zoë A Hughes; Merja Haaparanta-Solin; Vladimir Stepanov; Ryuji Nakao; Katarina Varnäs; Andrea Varrone; Eveliina Arponen; Päivi Marjamäki; Katariina Pohjanoksa; Lauri Vuorilehto; Phebian A Babalola; Olof Solin; Sarah Grimwood; Jukka Sallinen; Lars Farde; Mika Scheinin; Christer Halldin Journal: Int J Neuropsychopharmacol Date: 2014-12-13 Impact factor: 5.176
Authors: Sjoerd J Finnema; Mika Scheinin; Mohammed Shahid; Jussi Lehto; Edilio Borroni; Benny Bang-Andersen; Jukka Sallinen; Erik Wong; Lars Farde; Christer Halldin; Sarah Grimwood Journal: Psychopharmacology (Berl) Date: 2015-04-30 Impact factor: 4.530
Authors: Juha O Rinne; Keith Wesnes; Jeffrey L Cummings; Pasi Hakulinen; Merja Hallikainen; Jutta Hänninen; Michael Murphy; Henry Riordan; Mika Scheinin; Hilkka Soininen; Juha Rouru Journal: Alzheimers Dement (N Y) Date: 2016-12-08
Authors: Mohammed Shahid; Juha O Rinne; Mika Scheinin; Jere Virta; Päivi Marjamäki; Olof Solin; Eveliina Arponen; Jukka Sallinen; Katja Kuokkanen; Juha Rouru Journal: EJNMMI Res Date: 2020-12-09 Impact factor: 3.138
Authors: Mika Scheinin; Jussi Lehto; Jarkko Johansson; Pauliina Luoto; Eveliina Arponen; Lauri Vuorilehto; Harry Scheinin; Juha Rouru Journal: Springerplus Date: 2015-06-12